17:05, 4 September, 2020
YEREVAN, SEPTEMBER 4, ARMENPRESS. Sputnik V coronavirus vaccine generated a stable humoral and cellular immune response in 100% of participants in the clinical trials, the Russian Direct Investment Fund (RDIF) said in a news release.
A scientific article on the results of Phase I-II clinical trials of the world’s first registered coronavirus vaccine, Sputnik V has been published at The Lancet earlier today. “In 100% of participants in the clinical trials, Sputnik V generated a stable humoral and cellular immune response”, the statement says. “The level of virus-neutralizing antibodies of volunteers vaccinated with Sputnik V was 1.4-1.5 times higher than the level of antibodies of patients who had recovered from COVID-19. The level of virus-neutralizing antibodies of volunteers vaccinated with Sputnik V was 1.4-1.5 times higher than the level of antibodies of patients who had recovered from COVID-19”.
Phase I-II clinical trials of Sputnik V showed no serious adverse events (SAE, Grade 3) for any of the criteria, while the incidence of serious adverse events for other candidate vaccines ranged from 1% to 25%, the RDIF said.
On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Center of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against COVID-19.
Disclaimer: This article was contributed and translated into English by Badalian Vardan. While we strive for quality, the views and accuracy of the content remain the responsibility of the contributor. Please verify all facts independently before reposting or citing.
Direct link to this article: https://www.armenianclub.com/2020/09/05/results-of-phase-i-ii-clinical-trials-of-russian-vaccine-against-covid-19-announced/